AI Article Synopsis
- Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor, used in treating epithelial cancers, often alongside other treatments to boost effectiveness.
- The text discusses a unique case of unilateral acneiform eruption caused by cetuximab in a patient with facial palsy, differing from the more common bilateral symptoms.
- The authors suggest that reduced lymphatic drainage due to facial palsy may contribute to the localized effects of cetuximab, a phenomenon not previously documented in medical literature.
Article Abstract
Background: Cetuximab is a chimeric monoclonal antibody selective for epidermal growth factor receptor (EGFR). It is increasingly used in epithelial cancer, often in combination with radiotherapy or chemotherapeutic agents, since it induces a broad range of cellular responses that enhance tumour sensitivity to these therapies. However, it can cause numerous adverse effects, the most common being acneiform eruption on the face and trunk, which is generally bilateral and symmetric.
Patients And Methods: Herein we present the first case of unilateral cetuximab-induced acneiform eruption in facial palsy.
Discussion: To our knowledge the medical literature contains no other such cases. Our hypothesis is that lymphoedema associated with facial palsy reduces lymphatic drainage, promoting the deposition of cetuximab on EGFR and persistence of local signs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.annder.2010.06.026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Widening access to isotretinoin in primary care: an evaluation of New Zealand national dispensing data for isotretinoin for acne, 2008-2023.
BMJ Open
January 2025
General Practice and Primary Health Care, The University of Auckland Faculty of Medical and Health Sciences, Auckland, New Zealand
Objectives: To identify what changes in the prescribing of isotretinoin have occurred since funded prescriber access was widened in 2009 from 'dermatologist only' prescribing to include 'general practitioners (GPs) and nurse practitioners working within their scope of practice'.
Design: Evaluation of isotretinoin dispensing data from 2008 to 2023 using the national annual prescribing data obtained from the New Zealand Pharmaceutical National Collection database.
Setting: All New Zealand citizens prescribed and dispensed funded isotretinoin for acne from 2008 to 2023 were included.
Efficacy of diluted botulinum toxin type A (Microbotox) in treatment of mild to moderate acne vulgaris.
Arch Dermatol Res
January 2025
Department of Dermatology, Medical Research and Clinical Studies Institute, National Research Centre, Giza, Egypt.
Acne vulgaris is a common and challenging condition to treat. To assess the effect of botulinum toxin type A (BTX-A) in the treatment of mild to moderate acne vulgaris. This study included 30 patients with mild to moderate acne vulgaris treated with intradermal injections of diluted BTX-A (microbotox) on the cheek in a regular grid pattern using very small droplets (microbotox).
View Article and Find Full Text PDFBackground: Acne is an inflammatory skin disease afflicting the majority of the world's population at some point in their lifetime, and is seen to be chronic in about 50% of cases. Acne leads to significant social withdrawal, depression, and disfiguring scars in many cases. Available treatments are characterized by high rates of relapse, dangerous side effects, and social stigma, which often leads to poor patient compliance and treatment failure.
View Article and Find Full Text PDFAssociated diseases and their effects on disease course in patients with chronic non-bacterial osteomyelitis: retrospective experience from a single center.
Clin Rheumatol
February 2025
Division of Pediatric Rheumatology and Nephrology, Department of Pediatrics, Ankara University Faculty of Medicine, Ankara, Turkey.
Objective: Chronic non-bacterial osteomyelitis (CNO) is a rare autoinflammatory bone disease associated with other chronic inflammatory diseases such as familial Mediterranean fever (FMF), juvenile idiopathic arthritis (JIA), spondylarthropathies, inflammatory bowel disease (IBD), and pyoderma gangrenosum. We aimed to describe the clinical and follow-up characteristics of patients with CNO and to compare findings between patients with and without comorbidities.
Methods: The clinical records of patients with CNO who were followed up in our pediatric rheumatology clinic between 2018 and 2023 were reviewed.
Background: Benzoyl peroxide (BPO) is widely used in dermatological aesthetics for treating acne and other skin conditions. However, its potential adverse reactions remain a concern.
Aims: This study aimed to investigate the application of BPO in dermatological aesthetics, analyze its associated adverse reactions, and provide insights into patient safety.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!